JAK3 and primary cutaneous T-cell non-Hodgkin lymphoma: A previous study reported the production of high levels of VEGF through JAK3- and JNK-dependent signal pathways from malignant T cells in CTCL, thus revealing potential new therapeutic targets in CTCL [39].